# Effect of BIA 5 1058 on Cardiac Repolarization

> **NCT03489005** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 49 (actual)

## Conditions studied

- Cardiovascular Disease
- Pulmonary Arterial Hypertension
- Heart Failure

## Interventions

- **DRUG:** BIA 5-1058
- **DRUG:** Placebo Oral Tablet
- **DRUG:** Moxifloxacin 400 mg

## Key facts

- **NCT ID:** NCT03489005
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-09
- **Primary completion:** 2018-10-05
- **Final completion:** 2018-10-05
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2020-12-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03489005

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03489005, "Effect of BIA 5 1058 on Cardiac Repolarization". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03489005. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*